SG10201811494SA - Methods of treating a pulmonary bacterial infection using fluoroquinolones - Google Patents

Methods of treating a pulmonary bacterial infection using fluoroquinolones

Info

Publication number
SG10201811494SA
SG10201811494SA SG10201811494SA SG10201811494SA SG10201811494SA SG 10201811494S A SG10201811494S A SG 10201811494SA SG 10201811494S A SG10201811494S A SG 10201811494SA SG 10201811494S A SG10201811494S A SG 10201811494SA SG 10201811494S A SG10201811494S A SG 10201811494SA
Authority
SG
Singapore
Prior art keywords
methods
treating
bacterial infection
pulmonary bacterial
fluoroquinolones
Prior art date
Application number
SG10201811494SA
Other languages
English (en)
Inventor
Mike Dudley
David Griffith
Olga Rodny
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43011488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201811494S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of SG10201811494SA publication Critical patent/SG10201811494SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
SG10201811494SA 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoroquinolones SG10201811494SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17262509P 2009-04-24 2009-04-24

Publications (1)

Publication Number Publication Date
SG10201811494SA true SG10201811494SA (en) 2019-01-30

Family

ID=43011488

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201811494SA SG10201811494SA (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoroquinolones
SG10201403512TA SG10201403512TA (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones
SG2011076932A SG175288A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201403512TA SG10201403512TA (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones
SG2011076932A SG175288A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Country Status (27)

Country Link
US (2) US20120035166A1 (el)
EP (1) EP2421539B1 (el)
JP (2) JP6179844B2 (el)
KR (1) KR20120034626A (el)
CN (2) CN107050032A (el)
AU (1) AU2010238765B2 (el)
BR (1) BRPI1006626B8 (el)
CA (1) CA2759874C (el)
CL (1) CL2011002649A1 (el)
CO (1) CO6450642A2 (el)
CY (1) CY1122525T1 (el)
DK (1) DK2421539T3 (el)
ES (1) ES2755754T3 (el)
HR (1) HRP20191951T1 (el)
HU (1) HUE046595T2 (el)
IL (1) IL215777A (el)
LT (1) LT2421539T (el)
MX (1) MX339077B (el)
MY (1) MY178871A (el)
NZ (1) NZ596245A (el)
PL (1) PL2421539T3 (el)
PT (1) PT2421539T (el)
RU (1) RU2535056C2 (el)
SG (3) SG10201811494SA (el)
SI (1) SI2421539T1 (el)
WO (1) WO2010124141A1 (el)
ZA (1) ZA201107903B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
WO2014152326A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6966835B2 (ja) * 2016-02-05 2021-11-17 ホライズン オーファン リミテッド ライアビリティ カンパニー 嚢胞性線維症のためのフルオロキノロン製剤
CN108849939B (zh) * 2018-07-31 2021-02-19 广东省农业科学院植物保护研究所 盐酸左氧氟沙星在制备用于防治烟草青枯病的农药制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225689B2 (en) * 2002-03-05 2009-03-26 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2009246217B2 (en) 2008-05-15 2013-01-10 Novartis Ag Pulmonary delivery of a fluoroquinolone
KR20110091510A (ko) * 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형

Also Published As

Publication number Publication date
EP2421539B1 (en) 2019-10-23
AU2010238765B2 (en) 2014-12-18
IL215777A0 (en) 2012-01-31
SI2421539T1 (sl) 2019-12-31
CO6450642A2 (es) 2012-05-31
PL2421539T3 (pl) 2020-02-28
JP6179844B2 (ja) 2017-08-16
EP2421539A1 (en) 2012-02-29
ZA201107903B (en) 2013-01-30
SG10201403512TA (en) 2014-08-28
CN107050032A (zh) 2017-08-18
CL2011002649A1 (es) 2012-06-22
US20210015811A1 (en) 2021-01-21
EP2421539A4 (en) 2014-01-29
SG175288A1 (en) 2011-11-28
MY178871A (en) 2020-10-21
BRPI1006626A2 (pt) 2020-07-28
ES2755754T3 (es) 2020-04-23
JP2012524811A (ja) 2012-10-18
CA2759874C (en) 2016-11-08
MX339077B (es) 2016-05-10
CA2759874A1 (en) 2010-10-28
HRP20191951T1 (hr) 2021-05-14
US20120035166A1 (en) 2012-02-09
DK2421539T3 (da) 2019-11-18
NZ596245A (en) 2013-11-29
LT2421539T (lt) 2019-12-10
IL215777A (en) 2017-09-28
BRPI1006626B8 (pt) 2021-05-25
JP2016053041A (ja) 2016-04-14
AU2010238765A1 (en) 2011-11-10
PT2421539T (pt) 2019-11-22
BRPI1006626B1 (pt) 2021-05-11
KR20120034626A (ko) 2012-04-12
WO2010124141A1 (en) 2010-10-28
CY1122525T1 (el) 2021-01-27
CN102427815A (zh) 2012-04-25
RU2011145430A (ru) 2013-05-27
HUE046595T2 (hu) 2020-03-30
MX2011011190A (es) 2012-02-13
RU2535056C2 (ru) 2014-12-10
JP6228580B2 (ja) 2017-11-08

Similar Documents

Publication Publication Date Title
SG10201811494SA (en) Methods of treating a pulmonary bacterial infection using fluoroquinolones
PH12014502683B1 (en) NOVEL á-LACTAMASE INHIBITOR AND METHOD FOR PREPARING THE SAME
NZ593111A (en) Antibacterial compounds
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
NZ708928A (en) Mannose derivatives for treating bacterial infections
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
SG178952A1 (en) Chemical compounds
MX366793B (es) Metodos para preparar oxazolidinonas y composiciones que las contienen.
MX339455B (es) Inhibidores de pirimidina y topoisomerasa iv.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
NZ628927A (en) Compounds and methods for treating candidiasis and aspergillus infections
MX2013008164A (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
IN2012DN03846A (el)
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
MX2013007053A (es) Uso de compuestos que libera peroxigeno libre de nitrogeno para reducir el crecimiento de microorganismos contaminates en la fermentacion de etanol.
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
NZ713357A (en) Antimicrobial compounds and methods of making and using the same
EA201100754A1 (ru) [4-(1-аминоэтил)циклогексил]метиламины в качестве антибактериальных средств
WO2012085255A3 (en) Volatile organic compounds from bacterial antagonists for controlling microbial growth
MX2009009074A (es) Macrolidos basados en eritromicina.
MX2011008755A (es) Metodo para elaborar una composicion de bacterias de acido lactico.